PFS and OS according to baseline characteristics, univariate comparison, and censoring at transplant
| . | PFS . | OS . | ||
|---|---|---|---|---|
| Crude HR (95% CI) . | P* . | Crude HR (95% CI) . | P* . | |
| Baseline characteristics (reference†vs comparison) | ||||
| ISS disease stage at diagnosis (I vs II/III) | 1.12 (0.60-2.12) | .71 | 1.96 (0.91-4.19) | .09 |
| Durie-Salmon disease stage at diagnosis (I vs II/III) | 1.51 (0.71-3.21) | .29 | 2.22 (0.79-6.26) | .13 |
| Current disease status (relapsed vs relapsed/refractory) | 1.16 (0.68-1.97) | .59 | 1.58 (0.85-2.96) | .15 |
| β2-microglobulin, mg/L (<3.5 vs ≥3.5) | 1.08 (0.63-1.86) | .77 | 1.64 (0.85-3.13) | .14 |
| Albumin, g/dL (<3.5 vs ≥3.5) | 0.91 (0.44-1.88) | .80 | 1.27 (0.53-3.04) | .59 |
| Hemoglobin, g/dL (<12 vs ≥12) | 0.34 (0.18-0.63) | .0006 | 0.40 (0.20-0.82) | .01 |
| Serum calcium, g/dL (<10 vs 10-12) | 1.45 (0.72-2.92) | .29 | 0.92 (0.38-2.20) | .84 |
| Elevated LDH (no vs yes) | 1.61 (0.79-3.28) | .19 | 2.59 (1.22-5.52) | .01 |
| Cytogenetics‡ | ||||
| Abnormal cytogenetics by metaphase karyotyping (no vs yes) | 1.04 (0.56-1.92) | .91 | 1.33 (0.63-2.80) | .45 |
| Presence of del13/13q by FISH (no vs yes) | 1.55 (0.78-3.10) | .21 | 2.59 (1.06-6.34) | .04 |
| Presence of del17p by FISH (no vs yes) | 0.85 (0.34-2.08) | .72 | 1.82 (0.65-5.04) | .25 |
| Presence of t(4;14) by FISH (no vs yes) | 0.56 (0.17-1.87) | .35 | 0.56 (0.13-2.37) | .43 |
| Presence of del17p and/or t(4;14) by FISH (no vs yes) | 0.89 (0.39-2.02) | .78 | 1.69 (0.67-4.22) | .26 |
| . | PFS . | OS . | ||
|---|---|---|---|---|
| Crude HR (95% CI) . | P* . | Crude HR (95% CI) . | P* . | |
| Baseline characteristics (reference†vs comparison) | ||||
| ISS disease stage at diagnosis (I vs II/III) | 1.12 (0.60-2.12) | .71 | 1.96 (0.91-4.19) | .09 |
| Durie-Salmon disease stage at diagnosis (I vs II/III) | 1.51 (0.71-3.21) | .29 | 2.22 (0.79-6.26) | .13 |
| Current disease status (relapsed vs relapsed/refractory) | 1.16 (0.68-1.97) | .59 | 1.58 (0.85-2.96) | .15 |
| β2-microglobulin, mg/L (<3.5 vs ≥3.5) | 1.08 (0.63-1.86) | .77 | 1.64 (0.85-3.13) | .14 |
| Albumin, g/dL (<3.5 vs ≥3.5) | 0.91 (0.44-1.88) | .80 | 1.27 (0.53-3.04) | .59 |
| Hemoglobin, g/dL (<12 vs ≥12) | 0.34 (0.18-0.63) | .0006 | 0.40 (0.20-0.82) | .01 |
| Serum calcium, g/dL (<10 vs 10-12) | 1.45 (0.72-2.92) | .29 | 0.92 (0.38-2.20) | .84 |
| Elevated LDH (no vs yes) | 1.61 (0.79-3.28) | .19 | 2.59 (1.22-5.52) | .01 |
| Cytogenetics‡ | ||||
| Abnormal cytogenetics by metaphase karyotyping (no vs yes) | 1.04 (0.56-1.92) | .91 | 1.33 (0.63-2.80) | .45 |
| Presence of del13/13q by FISH (no vs yes) | 1.55 (0.78-3.10) | .21 | 2.59 (1.06-6.34) | .04 |
| Presence of del17p by FISH (no vs yes) | 0.85 (0.34-2.08) | .72 | 1.82 (0.65-5.04) | .25 |
| Presence of t(4;14) by FISH (no vs yes) | 0.56 (0.17-1.87) | .35 | 0.56 (0.13-2.37) | .43 |
| Presence of del17p and/or t(4;14) by FISH (no vs yes) | 0.89 (0.39-2.02) | .78 | 1.69 (0.67-4.22) | .26 |
Wald χ-square P value.
Reference groups: ISS stage I, Durie-Salmon stage 1, disease status-relapsed, β2-microglobulin <3.5 g/dL, albumin <3.5 g/dL, hemoglobin <12 g/dL, calcium <10 g/dL, no elevated LDH, normal metaphase and FISH cytogenetics. Number of patients with missing clinical characteristics: ISS at diagnosis (N = 16), Durie-Salmon stage at diagnosis (N = 1), β2-microglobulin (N = 3), albumin (N = 1), elevated LDH (N = 5). Number of patients with cytogenetics results are provided by abnormality type and noted in parentheses: metaphase cytogenetics (N = 60), del13q (N = 41), del17p (N = 36), t(4;14) (N = 37), t(11;14) (N = 38), t(14;16) (N = 13); other immunoglobulin H translocation (N = 34), del17p and/or t(4;14) (N = 33).
PFS and OS not assessed according to presence/absence of t(14;16) because data were available in only 13 patients (unknown status in 51 patients).